The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
Conditions
- Obesity
- Obesity; Drug
- Overweight or Obesity
- Weight Loss
- Weight Loss Trajectory
- Weight, Body
Intervention
- Semaglutide 2.4mg
- Placebo
Principal Investigator
- Peters, Warren
Sponsor
- Novo Nordisk
*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/16/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.
Request Information
Complete the form below to contact the study team and receive more information about this trial.